Engineered immune cells take on childhood leukemia in new trial
NCT ID NCT04276870
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a personalized cell therapy called CART19 in children and young adults with certain high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study aims to see if this treatment can improve event-free survival—meaning keeping the cancer from coming back—in patients who have limited options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CART19 cells (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could offer a powerful treatment option for children with aggressive or relapsed B-ALL who have few alternatives.
What could go wrong
This is a mid-stage trial with a relatively small number of participants. CAR T-cell therapy can cause severe side effects like cytokine release syndrome, and long-term outcomes are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••